Clinical Trials Browser

OTHER × lirilumab × Other hematologic neoplasm × Clear all

NCT02481297 2020-05-28

Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients

Phase 2 Completed

7 enrolled 11 charts

LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Lymphoid, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02599649 2020-01-14

Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)

Phase 2 Terminated

10 enrolled 8 charts

MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes

NCT02399917 2019-09-24

Lirilumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia

Phase 2 Terminated

36 enrolled 14 charts

Other hematologic neoplasm

Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute